Fig. 6

Schematic presentation of how competition with MBD proteins may affect TF binding. Each panel shows how in vitro-observed mCpG preferences may present themselves in vivo in the presence of competing mCpG-binding proteins such as MBDs. The percentages indicate the estimated frequency of each scenario among CpG-binding TFs. For example, 80% (4 out of 5) of JAMS-based methyl-plus TFs that have SELEX data show methyl-plus preference in vitro, and a total of 16 methyl-plus TFs are identified by JAMS. Therefore, ~ 13 out of these 16 TFs are expected to be in vitro methyl-plus TFs that remain methyl-plus in vivo, corresponding to ~ 6% (13 out of 204) of all CpG-binding TFs